68Ga-FAPI-46 PET/CT在胆管癌患者中的肿瘤检出优于18F-FDG PET/CT和常规CT
该前瞻性观察性试验分析10例胆管癌患者,比较68Ga-FAPI-46 PET/CT与18F-FDG PET/CT及常规CT的检出效能。68Ga-FAPI-46在原发灶、淋巴结和远处转移的检出率分别为5、11、6,高于18F-FDG的5、10、4和CT的5、3、2;原发灶SUVmax为14.5 vs 5.2(P=0.043)。结论认为68Ga-FAPI-46摄取优于18F-FDG,尤其在3级肿瘤中,准确性正在 ongoing 研究者发起试验中研究。
要点
- 68Ga-FAPI-46 PET/CT对淋巴结和远处转移的检出数高于18F-FDG PET/CT和常规CT。
- 原发灶SUVmax 68Ga-FAPI-46为14.5,18F-FDG为5.2(P=0.043)。
- 3级肿瘤68Ga-FAPI-46摄取显著高于2级肿瘤(SUVmax 12.6 vs 6.4,P=0.009)。
核心结论
- 68Ga-FAPI-46在胆管癌患者中表现出优于18F-FDG的放射性示踪剂摄取,尤其在3级肿瘤中,并且病灶检出更优。
- 免疫组化显示肿瘤间质FAP高表达,与上述结果一致。
- 准确性正在一项进行中的研究者发起试验中研究。
研究设计与样本
- 来自一项前瞻性观察性试验的胆管癌患者分析。
- 共10例患者(肝内胆管癌6例,肝外胆管癌4例;2级肿瘤6例,3级肿瘤4例)接受68Ga-FAPI-46 PET/CT和常规CT;其中9例额外接受18F-FDG PET/CT。
- 对6例患者整个中心肿瘤平面进行免疫组化FAP和GLUT1表达分析。
- 通过发送给治疗医师的PET/CT前后问卷(8例返回完整问卷)评估对治疗管理的影响。
主要发现
- 原发灶检出率:68Ga-FAPI-46 PET/CT为5,18F-FDG PET/CT为5,CT为5。
- 淋巴结检出率:68Ga-FAPI-46 PET/CT为11,18F-FDG PET/CT为10,CT为3。
- 远处转移检出率:68Ga-FAPI-46 PET/CT为6,18F-FDG PET/CT为4,CT为2。
- 原发灶SUVmax:68Ga-FAPI-46为14.5 vs 18F-FDG为5.2(P=0.043);淋巴结SUVmax:4.7 vs 6.7(P=0.05);远处转移SUVmax:9.5 vs 5.3(P=0.046)。
- 原发灶肿瘤/本底比(肝脏):68Ga-FAPI-46为12.1 vs 18F-FDG为1.9(P=0.043)。
临床怎么用
- 原文结论未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Management of cholangiocarcinoma is among other factors critically determined by accurate staging. Here, we aimed to assess the accuracy of PET/CT with the novel cancer fibroblast-directed 68Ga-fibroblast activation protein (FAP) inhibitor (FAPI)-46 tracer for cholangiocarcinoma staging and management guidance. Methods: Patients with cholangiocarcinoma from a prospective observational trial were analyzed. 68Ga-FAPI-46 PET/CT detection efficacy was compared with 18F-FDG PET/CT and conventional CT. SUVmax/tumor-to-background ratio (Wilcoxon test) and separately uptake for tumor grade and location (Mann-Whitney U test) were compared. Immunohistochemical FAP and glucose transporter 1 (GLUT1) expression of stromal and cancer cells was analyzed. The impact on therapy management was investigated by pre- and post-PET/CT questionnaires sent to the treating physicians. Results: In total, 10 patients (6 with intrahepatic cholangiocarcinoma and 4 with extrahepatic cholangiocarcinoma; 6 with grade 2 tumor and 4 with grade 3 tumor) underwent 68Ga-FAPI-46 PET/CT and conventional CT; 9 patients underwent additional 18F-FDG PET/CT. Immunohistochemical analysis was performed on the entire central tumor plain in 6 patients. Completed questionnaires were returned in 8 cases. Detection rates for 68Ga-FAPI-46 PET/CT, 18F-FDG PET/CT, and CT were 5, 5, and 5, respectively, for primary tumor; 11, 10, and 3, respectively, for lymph nodes; and 6, 4, and 2, respectively, for distant metastases. 68Ga-FAPI-46 versus 18F-FDG PET/CT SUVmax for primary tumor, lymph nodes, and distant metastases was 14.5 versus 5.2 (P = 0.043), 4.7 versus 6.7 (P = 0.05), and 9.5 versus 5.3 (P = 0.046), respectively, and tumor-to-background ratio (liver) was 12.1 versus 1.9 (P = 0.043) for primary tumor. Grade 3 tumors demonstrated a significantly higher 68Ga-FAPI-46 uptake than grade 2 tumors (SUVmax, 12.6 vs. 6.4; P = 0.009). Immunohistochemical FAP expression was high on tumor stroma (∼90% of cells positive), whereas GLUT1 expression was high on tumor cells (∼80% of cells positive). Overall, average expression intensity was estimated as grade 3 for FAP and grade 2 for GLUT1. Positive 68Ga-FAPI-46 PET findings led to a consequent biopsy workup and diagnosis of cholangiocarcinoma in 1 patient. However, patient treatment was not adjusted on the basis of 68Ga-FAPI-46 PET. Conclusion: 68Ga-FAPI-46 demonstrated superior radiotracer uptake, especially in grade 3 tumors, and lesion detection in patients with cholangiocarcinoma. In line with this result, immunohistochemistry demonstrated high FAP expression on tumor stroma. Accuracy is under investigation in an ongoing investigator-initiated trial.
引用
- Pabst KM, Trajkovic-Arsic M, Cheung PFY, et al. Superior Tumor Detection for 68Ga-FAPI-46 Versus 18F-FDG PET/CT and Conventional CT in Patients with Cholangiocarcinoma. J Nucl Med. 2023. PMID: 37024301. doi:10.2967/jnumed.122.265215
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。